Canada's KP Tissue Q3 revenue rises on higher sales volumes

By Reuters News


Overview

  • Canada tissue maker's Q3 revenue rose 5.1% yr/yr on higher sales volumes and pricing

  • Adjusted EBITDA for Q3 rose 9.1% yr/yr

  • Q3 net income more than doubled from a year ago


Outlook

  • Company expects Q4 2026 Adjusted EBITDA to be slightly below Q3, but above Q4 2025

  • Company expects escalating input costs and inflationary pressure in coming quarters

  • Company anticipates delay in new TAD facility, not commencing operations in 2028


Result Drivers

  • CONSUMER SEGMENT GROWTH - Higher sales volumes in the Consumer segment and favourable selling prices in the U.S. Consumer business drove revenue gains

  • COST PRESSURES - Increased manufacturing overhead, higher freight and warehousing costs, and foreign exchange impacts raised costs, partially offset by lower pulp costs

  • BRAND INVESTMENT - Continued investment in brands contributed to sales growth in both Canada and the U.S.


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

C$589.66 mln

C$574.90 mln (2 Analysts)

Q3 Net Income

C$27.71 mln

Q3 Adjusted EBITDA

C$93.50 mln

Q3 Operating Income

C$59.81 mln

Q3 Pretax Profit

C$41.81 mln


Reuters Recommended Reads

  • Nov 10 - Canada's CCL Industries Q3 sales rise driven by Avery, CCL, Innovia

  • Nov 10 - Canada's Pet Valu Q3 revenue beats estimates on retail sales; lifts outlook

  • Nov 9 - Hain Celestial Q1 sales misses estimates


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk